IP Library Granted Patent US 9,611,201
Granted Patent B2
US 9,611,201 · App. 15/059,627 · Granted Apr 4, 2017

Processes for preparing (R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanol and 1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanone

Inventors: Stéphane De Lombaert (Brisbane, CA); Daniel R. Goldberg (Redding, CT)
Assignee: Karos Pharmaceuticals, Inc.
C07C29/32C07C29/143C07C45/455C07C49/80C07C259/10C07B2200/07
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,611,201
App. No.
15/059,627
Granted
Apr 4, 2017
Kind
B2
Abstract

The present invention relates to processes for the preparation of (R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanol, 1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanone, and intermediates thereof, which are useful in the preparation of inhibitors of TPH1 for the treatment of, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, low bone mass diseases, serotonin syndrome, and cancer.

Claims (14)

1. A process for preparing a compound of Formula B:

comprising reacting a compound of Formula 1-3:

wherein X is selected from Br and I,

with phenylboronic acid to produce the compound of Formula B.

2. The process of claim 1 , wherein X is I.

3. The process of claim 1 , wherein X is Br.

4. The process of claim 1 , wherein said reacting is carried out under Suzuki coupling conditions.

5. The process of claim 1 , wherein said reacting is carried out in the presence of a Pd catalyst.

6. The process of claim 5 , wherein said Pd catalyst is Pd 2 (dppf)Cl 2 .

7. The process of claim 1 , wherein said reacting is carried out in the presence of a solvent.

8. The process of claim 7 , wherein said solvent comprises dioxane.

9. The process of claim 7 , wherein said solvent comprises aqueous sodium carbonate.

10. The process of claim 1 , wherein said reacting is carried out at elevated temperature.

11. The process of claim 10 , wherein said elevated temperature is about 90° C.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 1, 2021
From: ROIVANT SCIENCES GMBH
To: ALTAVANT SCIENCES GMBH
Reel/Frame 055793/0133 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 8, 2017
From: KAROS PHARMACEUTICALS, INC.
To: ROIVANT SCIENCES GMBH
Reel/Frame 044069/0338 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 27, 2017
From: KAROS PHARMACEUTICALS, INC.
To: ROIVANT SCIENCES GMBH
Reel/Frame 043716/0336 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 24, 2016
From: LOMBAERT, STEPHANE DE; GOLDBERG, DANIEL R.
To: KAROS PHARMACEUTICALS, INC.
Reel/Frame 038090/0876 →
Continuity (2)
Provisional Application 62128652 · Mar 5, 2015
Related Publication 20160257633A1 · Sep 8, 2016